B6-huAPRIL (huTNFSF13) Mouse
製品名
B6-huAPRIL (huTNFSF13) Mouse
製品ID
C001852
系統名
C57BL/6NCya-Tnfsf13tm1(hTNFSF13)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「B6-huAPRIL (huTNFSF13) Mouse（カタログ番号C001852）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
APRIL, CD256, TALL2, ZTNF2, TALL-2, TNLG7B, TRDL-1, UNQ383/PRO715
NCBI ID
染色体
Chr 17
MGI ID
さらに
系統詳細
The TNFSF13 gene, also known as APRIL (a proliferation-inducing ligand), encodes a critical member of the tumor necrosis factor (TNF) superfamily. Its expression is detected in various cell types within the immune and stromal compartments, including monocytes, macrophages, dendritic cells, and bone marrow precursors [1]. The encoded cytokine functions by binding to specific receptors, namely TNFRSF17/BCMA and TNFRSF13B/TACI, thereby regulating key aspects of B cell and plasma cell biology, including their development and long-term survival. TNFSF13 is instrumental in the adaptive immune response, facilitating antibody class switching and providing essential survival cues to antibody-secreting cells [2]. Dysregulated TNFSF13 expression has been etiologically linked to various pathologies. Aberrant TNFSF13 signaling contributes to the pathogenesis of multiple myeloma and chronic lymphocytic leukemia (CLL) by promoting the proliferation and survival of malignant cells [3]. Furthermore, its dysregulation is also implicated in the progression of several autoimmune disorders, such as rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE) [4].
The B6-huAPRIL (huTNFSF13) mouse is a humanized model constructed via gene-editing technology. The sequence from the ATG start codon to the TGA stop codon of mouse Tnfsf13 is replaced with the sequence from the ATG start codon to the TGA stop codon of human TNFSF13. B6-huAPRIL (huTNFSF13) mice can be used for research into the pathogenesis of autoimmune disorders like rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE), as well as some cancers, and for the development of TNFSF13-targeted drugs.
参考文献
Chen R, Wang X, Dai Z, Wang Z, Wu W, Hu Z, Zhang X, Liu Z, Zhang H, Cheng Q. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas. Front Immunol. 2021 Oct 12;12:713757.
Poznyak AV, Gerasimova EV, Orekhov NA, Karimova AE, Vergun MA, Lapshina KO, Sukhorukov VN, Orekhov AN. Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome. Front Immunol. 2025 Aug 1;16:1523392.
Ullah MA, Mackay F. The BAFF-APRIL System in Cancer. Cancers (Basel). 2023 Mar 16;15(6):1791.
Muto M, Suzuki H, Suzuki Y. New Insights and Future Perspectives of APRIL in IgA Nephropathy. Int J Mol Sci. 2024 Sep 26;25(19):10340.
系統作製戦略
The sequences from the ATG start codon to the TGA stop codon of the endogenous mouse Tnfsf13 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFSF13 gene. The Neo cassette was inserted downstream of the TGA stop codon. The function of the mouse Tnfsfm13 and Tnfsf13os genes will be affected.
Figure 1. Gene editing strategy of B6-huAPRIL (huTNFSF13) mice.
適用分野
TNFSF13-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of certain cancers;
Research on the pathological mechanisms and therapeutic approaches of autoimmune disorders, such as rheumatoid arthritis (RA), IgA nephropathy, and systemic lupus erythematosus (SLE).
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。